Anakinra for refractory pustular psoriasis: A phase II, open-label, dose-escalation trial

Affiliations

• ¹ Department of Dermatology, University of California, San Francisco, California. Electronic address: Haley.Naik@ucsf.edu.
• ² Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland.
• ³ Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
• ⁴ Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland.
• ⁵ Clinical and Translational Immunology Unit, Laboratory of Immunology, National Eye Institute, Bethesda, Maryland.
• ⁶ Biostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
• ⁷ Division of Cancer Control and Population Sciences, Outcomes Research Branch, National Cancer Institute, Rockville, Maryland.
• ⁸ Translational Autoinflammatory Diseases Section (TADS), LCIM, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
• ⁹ Department of Dermatology, University of California, San Francisco, California; Department of Pathology, University of California, San Francisco, California.
• ¹⁰ Section of Inflammation and Cardiovascular Diseases, National Institute of Heart, Lung and Blood Diseases, Bethesda, Maryland.
• ¹¹ Biodata Mining and Discovery Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland.